81 FR 36932 - Findings of Research Misconduct

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary

Federal Register Volume 81, Issue 110 (June 8, 2016)

Page Range		36932-36933
FR Document		2016-13541

Notice is hereby given that the Office of Research Integrity (ORI) has taken final action in the following case: Meredyth M. Forbes, Albert Einstein College of Medicine: Based on an assessment conducted by the Albert Einstein College of Medicine (AECM), an admission from the Respondent, and additional analysis conducted by ORI in its oversight review, ORI found that Ms. Meredyth M. Forbes, former Graduate Student, AECM, engaged in research misconduct in research supported by National Institute of General Medical Sciences (NIGMS), National Institutes of Health (NIH), grants R01 GM089979, T32 GM007491, R01 GM55101, and R01 GM88202 and National Institute of Child Health and Human Development (NICHD), NIH, grant T32 HD007502. ORI found that Respondent engaged in research misconduct by intentionally falsifying and/or fabricating data reported in the following three (3) published papers and four (4) meeting presentations:

Federal Register, Volume 81 Issue 110 (Wednesday, June 8, 2016)

[Federal Register Volume 81, Number 110 (Wednesday, June 8, 2016)]
[Notices]
[Pages 36932-36933]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-13541]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary


Findings of Research Misconduct

AGENCY: Office of the Secretary, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the Office of Research Integrity 
(ORI) has taken final action in the following case:
    Meredyth M. Forbes, Albert Einstein College of Medicine: Based on 
an assessment conducted by the Albert Einstein College of Medicine 
(AECM), an admission from the Respondent, and additional analysis 
conducted by ORI in its oversight review, ORI found that Ms. Meredyth 
M. Forbes, former Graduate Student, AECM, engaged in research 
misconduct in research supported by National Institute of General 
Medical Sciences (NIGMS), National Institutes of Health (NIH), grants 
R01 GM089979, T32 GM007491, R01 GM55101, and R01 GM88202 and National 
Institute of Child Health and Human Development (NICHD), NIH, grant T32 
HD007502.
    ORI found that Respondent engaged in research misconduct by 
intentionally falsifying and/or fabricating data reported in the 
following three (3) published papers and four (4) meeting 
presentations:

 Development. In press, published online, Dec 23, 2015; 
doi:10.1242/dev.129023 (hereafter referred to as the ``December 2015 
Development paper'')
 Cell Reports 12:49-57, 2015 (hereafter referred to as the 
``Cell Reports paper'')
 Development 142(15):2704-18, 2015 Aug 1 (hereafter referred to 
as the ``August 2015 Development paper'')
 ``Maternal dazap2 regulates germ granules via counteracting 
Dynein in zebrafish primordial germ cells.'' Laboratory Presentation, 
January 28, 2015 (hereafter referred to as the ``Lab Presentation 
2015'')
 ``Maternal dazap2 regulates germ granule formation in 
zebrafish primordial germ cells.'' Presented at the Germ Cells, Cold 
Spring Harbor, NY, October 2014, NYC-Wide Stem Cell Event, ``Stem Cells 
in the City,'' NY, November 2014, Mid-Atlantic Regional Zebrafish 
Meeting, PA, November 2014, and New York Metropolitan Zebrafish 
Meeting, Cornell, NY, January 2015 (hereafter referred to as ``Poster 
1, 2014-2015'')
 ``Cytoskeleton, microtubules, centrosomes, germline cyst, 
Bucky ball, oocytes.'' Poster presented at the Mid-Atlantic Regional 
Zebrafish Meeting, Bronx, NY, July 2015 (hereafter referred to as 
``MARZ 2015'')
 ``Bucky ball associates with the centrosome and promotes 
microtubule cytoskeleton rearrangements to establish oocyte polarity in 
zebrafish.'' Poster presented at the American Society for Cell Biology 
(ASCB) Meeting, San Diego, CA, December 2015 (hereafter referred to as 
``ACSB 2015'')

    ORI found that Respondent intentionally falsified and/or fabricated 
data for germ-cell development in zebrafish Dazap2 maternal-effect 
mutants (MDazap2) in one (1) paper and two (2) presentations when the 
mutants were not produced nor the data derived from them.
    Specifically, Respondent:
 falsified thirty-eight (38) fluorescent image panels by 
drawing staining in PhotoShop and falsely labeling them in Figures 1F, 
1G, 2A, 2C, 2E, 2F, 2G, 3A, 3D, 4A, and S2A in the Cell Reports paper 
and included some of the same images in seven (7) figures in Lab 
Presentation 2015 and in six (6) figures in Poster 1 2014-2015
 fabricated numbers for data presented in ten (10) graphs in 
Figures 1L, 2B, 2D, 2H, 3B, 4B, 4C, S2B, S2C, and S3B in the Cell 
Reports paper and included some of the same graphs in seven (7) figures 
in Lab Presentation 2015 and in six (6) figures in Poster 1 2014-2015

    ORI found that Respondent intentionally fabricated and/or falsified 
data for zebrafish embryogenesis and oocyte polarity in two (2) papers 
and two (2) presentations when the data were not obtained from actual 
experiments.
    Specifically, Respondent:
 falsified twenty-four (24) fluorescent image panels by drawing 
staining in Photoshop and falsely labeling them in Figures 5B, 5C, 5D, 
5E, 7A, 7B, 7D, 8A, 8B, 9A, and 9B in the August 2015 Development paper 
and included some of the same images in four (4) figures in the ASCB 
2015 poster and in two (2) figures in the MARZ 2015 poster

 fabricated numbers for data presented in eight (8) graphs and 
one (1) illustration in Figures 5F, 7C, 7E, 8C, 8F-I, 9C, and 9D in the 
December 2015 Development paper and Figure 2F in the August 2015 
Development paper and included some of the same graphs in four (4) 
figures in the ASCB 2015 poster and in two (2) figures in the MARZ 2015 
poster

[[Page 36933]]

    Ms. Forbes has entered into a Voluntary Exclusion Agreement 
(Agreement) and has voluntarily agreed for a period of three (3) years, 
beginning on May 6, 2016:
    (1) to exclude herself from any contracting or subcontracting with 
any agency of the United States Government and from eligibility or 
involvement in nonprocurement programs of the United States Government 
referred to as ``covered transactions'' pursuant to HHS' Implementation 
(2 CFR part 376 et seq.) of OMB Guidelines to Agencies on 
Governmentwide Debarment and Suspension, 2 CFR part 180 (collectively 
the ``Debarment Regulations'');
    (2) that she will neither apply for nor permit her name to be used 
on any application, proposal, or other request for funds to the United 
States Government or any of its agencies, as defined in the Debarment 
Regulations; Respondent will further ensure that during the period of 
the voluntary exclusion, she will neither receive nor be supported by 
funds of the United States Government and its agencies made available 
through grants, subgrants, cooperative agreements, contracts, or 
subcontracts, as discussed in the Debarment Regulations; and
    (3) to exclude herself from serving in any advisory capacity to the 
U.S. Public Health Service (PHS) including, but not limited to, service 
on any PHS advisory committee, board, and/or peer review committee, or 
as a consultant.

FOR FURTHER INFORMATION CONTACT:  Director, Office of Research 
Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 
453-8200.

Kathryn M. Partin,
Director, Office of Research Integrity.
[FR Doc. 2016-13541 Filed 6-7-16; 8:45 am]
 BILLING CODE 4150-31-P

Federal Register / Vol. 81, No. 110 / Wednesday, June 8, 2016 / Notices 36933

Ms. Forbes has entered into a and Integrative and Public Health (the www.surgeongeneral.gov/priorities/
Voluntary Exclusion Agreement ‘‘Advisory Group’’). This meeting will prevention/advisorygrp/.
(Agreement) and has voluntarily agreed be open to the public. Information about Members of the public have the
for a period of three (3) years, beginning the Advisory Group and the agenda for opportunity to participate in the
on May 6, 2016: this meeting can be obtained by meeting and/or provide comments to
(1) to exclude herself from any accessing the following Web site: http:// the Advisory Group on July 11, 2016.
contracting or subcontracting with any www.surgeongeneral.gov/priorities/ Public comment will be limited to 3
agency of the United States Government prevention/advisorygrp/index.html. minutes per speaker. Individuals who
and from eligibility or involvement in DATES: The meeting will be held on July wish to participate in the meeting and/
nonprocurement programs of the United 11, 2016, from 3:00 p.m.–5:00 p.m. EST. or provide comments must register by
States Government referred to as 12:00 p.m. EST on July 5, 2016. In order
‘‘covered transactions’’ pursuant to ADDRESSES: This meeting will be held
to register, individuals must send their
HHS’ Implementation (2 CFR part 376 et via teleconference. Teleconference
full name and affiliation via email to
seq.) of OMB Guidelines to Agencies on information and the exact meeting time
npcsupport@cdc.gov. Individuals who
Governmentwide Debarment and will be published closer to the meeting
need special assistance and/or
Suspension, 2 CFR part 180 (collectively date at: http://www.surgeongeneral.gov/
accommodations, i.e., sign language
the ‘‘Debarment Regulations’’); priorities/prevention/advisorygrp/
interpretation or other reasonable
(2) that she will neither apply for nor index.html.
accommodations, should indicate so
permit her name to be used on any FOR FURTHER INFORMATION CONTACT: when they register. Members of the
application, proposal, or other request Office of the Surgeon General, U.S. public who wish to have materials
for funds to the United States Department of Health and Human distributed to the Advisory Group
Government or any of its agencies, as Services, 200 Independence Ave. SW.; members at these scheduled meetings
defined in the Debarment Regulations; Washington, DC 20201; 202–205–9517; should submit those materials when
Respondent will further ensure that npcsupport@cdc.gov. they register.
during the period of the voluntary
SUPPLEMENTARY INFORMATION: The Dated: May 23, 2016.
exclusion, she will neither receive nor
Advisory Group is a non-discretionary Brigette Ulin,
be supported by funds of the United
States Government and its agencies federal advisory committee that was Designated Federal Officer, Advisory Group
made available through grants, initially established under Executive on Prevention, Health Promotion, and
subgrants, cooperative agreements, Order 13544, dated June 10, 2010, to Integrative and Public Health, Office of the
contracts, or subcontracts, as discussed comply with the statutes under Section Surgeon General.
in the Debarment Regulations; and 4001 of the Patient Protection and [FR Doc. 2016–13558 Filed 6–7–16; 8:45 am]
(3) to exclude herself from serving in Affordable Care Act, Public Law 111– BILLING CODE 4163–18–P
any advisory capacity to the U.S. Public 148. The Advisory Group was
Health Service (PHS) including, but not terminated on September 30, 2012, by
limited to, service on any PHS advisory Executive Order 13591, dated November DEPARTMENT OF HEALTH AND
committee, board, and/or peer review 23, 2011. Authority for the Advisory HUMAN SERVICES
committee, or as a consultant. Group to be re-established was given
under Executive Order 13631, dated National Institutes of Health
FOR FURTHER INFORMATION CONTACT:
December 7, 2012. Authority for the
Director, Office of Research Integrity, Prospective Grant of an Exclusive
Advisory Group to continue to operate
1101 Wootton Parkway, Suite 750, License: The Development of an Anti-
until September 30, 2017, was given
Rockville, MD 20852, (240) 453–8200. GPC3 Chimeric Antigen Receptor
under Executive Order 13708, dated
Kathryn M. Partin, September 30, 2015. (CAR) Based on HN3 for the Treatment
Director, Office of Research Integrity. The Advisory Group was established of Human Cancers
[FR Doc. 2016–13541 Filed 6–7–16; 8:45 am] to assist in carrying out the mission of AGENCY: National Institutes of Health,
BILLING CODE 4150–31–P the National Prevention, Health Public Health Service, HHS.
Promotion, and Public Health Council ACTION: Notice.
(the Council). The Advisory Group
DEPARTMENT OF HEALTH AND provides recommendations and advice SUMMARY: This notice, in accordance
HUMAN SERVICES to the Council. It is authorized for the with 35 U.S.C. 209(c)(1) and 37 CFR
Advisory Group to consist of not more Part 404.7(a)(1)(i), that the National
Meeting of the Advisory Group on than 25 non-federal members. The Institutes of Health, Department of
Prevention, Health Promotion, and Advisory Group currently has 21 Health and Human Services, is
Integrative and Public Health members who were appointed by the contemplating the grant of an exclusive
AGENCY: Office of the Surgeon General President. The membership includes a license to practice the inventions
of the United States Public Health diverse group of licensed health embodied in:
Service, Office of the Assistant Secretary professionals, including integrative Intellectual Property:
for Health, Office of the Secretary, health practitioners who have expertise U.S. Provisional Patent Application
Department of Health and Human in (1) worksite health promotion; (2) 61/477,020 entitled ‘‘Human
Services. community services, including Monoclonal Antibody Specific for
community health centers; (3) Glypican-3 And Use Thereof’’ [HHS Ref.
mstockstill on DSK3G9T082PROD with NOTICES

ACTION: Notice.
preventive medicine; (4) health E–130–2011/0–US–01], PCT Patent
SUMMARY: In accordance with Section coaching; (5) public health education; Application PCT/US2012/034186
10(a) of the Federal Advisory Committee (6) geriatrics; and (7) rehabilitation entitled ‘‘Human Monoclonal
Act, Public Law 92–463, as amended (5 medicine. Antibodies Specific for Glypican-3 And
U.S.C. App.), notice is hereby given that A meeting description and relevant Use Thereof’’ [HHS Ref. E–130–2011/0–
a meeting is scheduled for the Advisory materials will be published closer to the PCT–02], Chinese Patent Application
Group on Prevention, Health Promotion, meeting date at: http:// 201280029201.3 entitled ‘‘Human

VerDate Sep<11>2014 18:59 Jun 07, 2016 Jkt 238001 PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 E:\FR\FM\08JNN1.SGM 08JNN1

Document Created: 2016-06-08 03:10:45
Document Modified: 2016-06-08 03:10:45

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Action		Notice.
Contact		Director, Office of Research Integrity, 1101 Wootton Parkway, Suite 750, Rockville, MD 20852, (240) 453-8200.
FR Citation		81 FR 36932

81 FR 36932 - Findings of Research Misconduct

DEPARTMENT OF HEALTH AND HUMAN SERVICESOffice of the Secretary

Federal Register Volume 81, Issue 110 (June 8, 2016)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary